AzurRx BioPharma (AZRX) Earns Outperform Rating from Analysts at CIBC

CIBC initiated coverage on shares of AzurRx BioPharma (NASDAQ:AZRX) in a research report sent to investors on Wednesday morning. The brokerage issued an outperform rating and a $6.00 target price on the stock.

A number of other research analysts have also recently issued reports on the stock. HC Wainwright reissued a buy rating and set a $6.00 price target on shares of AzurRx BioPharma in a research report on Friday, August 17th. Oppenheimer started coverage on shares of AzurRx BioPharma in a research report on Wednesday. They set an outperform rating and a $6.00 price target for the company.

Shares of NASDAQ AZRX opened at $2.64 on Wednesday. AzurRx BioPharma has a 1 year low of $2.10 and a 1 year high of $4.08.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Parsons Capital Management Inc. RI raised its holdings in AzurRx BioPharma by 20.3% in the first quarter. Parsons Capital Management Inc. RI now owns 329,515 shares of the company’s stock worth $1,035,000 after buying an additional 55,540 shares during the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new position in AzurRx BioPharma in the second quarter worth about $1,782,000. Opaleye Management Inc. purchased a new position in AzurRx BioPharma in the second quarter worth about $417,000. Ardsley Advisory Partners raised its holdings in AzurRx BioPharma by 66.3% in the second quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock worth $440,000 after buying an additional 54,697 shares during the last quarter. Finally, 683 Capital Management LLC purchased a new position in AzurRx BioPharma in the second quarter worth about $1,284,000. 18.61% of the stock is owned by institutional investors.

About AzurRx BioPharma

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Read More: What is insider trading?

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply